Linked Life Data

1672843

Source:http://linkedlifedata.com/resource/pubmed/id/1672843

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1991-5-10
pubmed:abstractText
In 20 patients with established coronary artery disease, stable angina pectoris and reproducible ST-segment depression, the pharmacokinetics and pharmacodynamic effects of 60 mg slow-release isosorbide-5-mononitrate (IS-5-MN) (10 patients) after a 7-day therapy were compared with those of a placebo group (10 patients) using a randomized double-blind, placebo-controlled study design. Ten patients could be controlled after long-term therapy over a mean of 399 +/- 111 days. There was no significant change under IS-5-MN of either blood pressure, heart rate, rate-pressure product, or myocardial oxygen consumption. Treatment over one week significantly reduced ST-segment depression 4 and 8 h after drug intake (38-48% of the placebo value, p less than 0.01). Maximum reduction in ST-segment depression was found 4 and 8 h after IS-5-MN intake both after one-week and long-term therapy at the time of peak plasma drug concentration (341 +/- 95 and 405 +/- 125 ng/ml, respectively). At a residual plasma concentration below 100 ng/ml, ST depression was not significantly improved 24 h after drug intake compared with placebo. Technetium-99m ventriculography showed an insignificant increase in ejection fraction and a slight reduction of ventricular volumes after both short- and long-term therapy with IS-5-MN (p greater than 0.05). The drug's plasma levels were higher under chronic than under short-term therapy which may be due to enzyme saturation. Maximum IS-5-MN plasma concentrations at a mean of 445 +/- 116 ng/ml were reached after 5.8 +/- 2.9 h. Beta-phase half-life of elimination was 9 +/- 3 h. IS-5-MN administered as a single 60 mg dose of a slow-release preparation/day proved to have a favorable pharmacokinetic profile as well as an efficient antiischemic activity after both short- and long-term therapy. Problems of tolerance or activation of hormonal counter-regulation due to vasodilation were not observed.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0160-9289
pubmed:author
pubmed:issnType
Print
pubmed:volume
14
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
209-18
pubmed:dateRevised
2005-11-17
pubmed:meshHeading
pubmed-meshheading:1672843-Adult, pubmed-meshheading:1672843-Aged, pubmed-meshheading:1672843-Angiotensin II, pubmed-meshheading:1672843-Blood Pressure, pubmed-meshheading:1672843-Coronary Disease, pubmed-meshheading:1672843-Delayed-Action Preparations, pubmed-meshheading:1672843-Double-Blind Method, pubmed-meshheading:1672843-Electrocardiography, pubmed-meshheading:1672843-Epinephrine, pubmed-meshheading:1672843-Heart Rate, pubmed-meshheading:1672843-Humans, pubmed-meshheading:1672843-Isosorbide Dinitrate, pubmed-meshheading:1672843-Middle Aged, pubmed-meshheading:1672843-Neurotransmitter Agents, pubmed-meshheading:1672843-Norepinephrine, pubmed-meshheading:1672843-Oxygen Consumption, pubmed-meshheading:1672843-Placebos, pubmed-meshheading:1672843-Renin, pubmed-meshheading:1672843-Time Factors, pubmed-meshheading:1672843-Vasopressins, pubmed-meshheading:1672843-Ventricular Function, Left
pubmed:year
1991
pubmed:articleTitle
Hemodynamic, anti-ischemic, and neurohumoral effects of slow-release isosorbide-5-mononitrate in patients with coronary artery disease after short- and long-term therapy.
pubmed:affiliation
Kerckhoff-Klinik of the Max-Planck-Society, Bad Nauheim, Germany.
pubmed:publicationType
Journal Article, Clinical Trial, Randomized Controlled Trial